Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study
Simon Rule, Wolney Gois Barreto, Javier Briones, Angelo M Carella, Olivier Casasnovas, Chris Pocock, Clemens-Martin Wendtner, Francesco Zaja, Susan Robson, Lachlan MacGregor, Roger R Tschopp, Sonja Nick, Martin Dreyling, Simon Rule, Wolney Gois Barreto, Javier Briones, Angelo M Carella, Olivier Casasnovas, Chris Pocock, Clemens-Martin Wendtner, Francesco Zaja, Susan Robson, Lachlan MacGregor, Roger R Tschopp, Sonja Nick, Martin Dreyling
Abstract
Rituximab plus chemotherapy induction followed by rituximab maintenance for up to 2 years confers a long-term benefit in terms of progression-free survival in patients with indolent non-Hodgkin lymphoma. It is not known whether further prolonged maintenance with rituximab provides additional benefit. The phase III MabCute study enrolled 692 patients with relapsed or refractory indolent non-Hodgkin lymphoma. Patients who responded to induction with rituximab plus chemotherapy and were still responding after up to 2 years' initial maintenance with subcutaneous rituximab were randomized to extended maintenance with subcutaneous rituximab (n=138) or observation only (n=138). The primary endpoint of investigator-assessed progression-free survival in the randomized population was un-addressed by the end of study because of an insufficient number of events (129 events were needed for 80% power at 5% significance if approximately 330 patients were randomized). In total, there were 46 progression-free survival events, 19 and 27 in the rituximab and observation arms, respectively (P=0.410 by stratified log-rank test; hazard ratio 0.76 [95% confidence interval: 0.37- 1.53]). The median progression-free survival was not reached in either randomized arm. There were no new safety signals; however, adverse events were seen slightly more frequently with rituximab than with observation during extended maintenance. Maintenance for up to 2 years with rituximab after response to initial induction therefore remains the standard of care in patients with relapsed or refractory indolent non- Hodgkin lymphoma. (Clinicaltrials.gov identifier: NCT01461928).
Figures
References
- Ninkovic S, Lambert J. Non-Hodgkin lymphoma. Medicine. 2017;45(5):297-304.
- Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet. 2012;380 (9844):848-857.
- Dreyling M, Ghielmini M, Rule S, et al. . Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow- up. Ann Oncol. 2021;32(3):298-308.
- Kastritis E, Leblond V, Dimopoulos MA, et al. . Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv41-iv50.
- Tilly H, Gomes da Silva M, Vitolo U, et al. . Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116-125.
- Zelenetz AD, Gordon LI, Abramson JS, et al. . NCCN guidelines insights: B-cell lymphomas, version 3.2019. J Natl Compr Canc Netw. 2019;17(6):650-661.
- Dreyling M, Campo E, Hermine O, et al. . Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow- up. Ann Oncol. 2017;28(Suppl 4):iv62-iv71.
- Salles G, Barrett M, Foa R, et al. . Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232-2273.
- MabThera Summary of Product Characteristics. 2020. (Accessed 27 April,. 2021, at ).
- Highlights of prescribing information. Rituxan® (rituximab) injection, for intravenous use. South San Francisco, CA: Biogen Idec, Inc. and Genentech USA, Inc.; 2019. September.
- Yelvington BJ. Subcutaneous rituximab in follicular lymphoma, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma. J Adv Pract Oncol. 2018;9(5):530-534.
- Davies A, Berge C, Boehnke A, et al. . Subcutaneous rituximab for the treatment of B-cell hematologic malignancies: a review of the scientific rationale and clinical development. Adv Ther. 2017;34(10):2210-2231.
- Davies A, Merli F, Mihaljevic B, et al. . Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol. 2014;15(3):343-352.
- Davies A, Merli F, Mihaljevic B, et al. . Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017;4(6): e272-e282.
- Lugtenburg P, Avivi I, Berenschot H, et al. . Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica. 2017;102(11):1913-1922.
- Assouline S, Buccheri V, Delmer A, et al. . Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled noninferiority trial. Lancet Haematol. 2016;3(3): e128-138.
- Rummel M, Kim TM, Aversa F, et al. . Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). Ann Oncol. 2017;28(4):836-842.
- De Cock E, Kritikou P, Sandoval M, et al. . Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries. PLoS One. 2016;11(6):e0157957.
- Highlights of prescribing information: Rituxan Hycela™ (rituximab and hyaluronidase human) injection, for subcutaneous use. San Francisco, CA: Genentech, Inc. 2017.
- Schneider T, Rosta A, Losonczy H, et al. . Efficacy and tolerability of a 2-year rituximab maintenance therapy in patients with advanced follicular lymphoma after induction of response with rituximab-containing first line-regimens (HUSOM Study). Pathol Oncol Res. 2018;24(2):199-205.
- Salles G, Seymour JF, Offner F, et al. . Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377 (9759):42-51.
- Forstpointner R, Dreyling M, Repp R, et al. . The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104(10):3064-3071.
- van Oers MH, Klasa R, Marcus RE, et al. . Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non- Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108(10):3295-3301.
- van Oers MH, Van Glabbeke M, Giurgea L, et al. . Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28(17):2853-2858.
- Oh SY, Kim WS, Kim JS, et al. . Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study. Cancer Commun (Lond) 2019;39(1):58.
- Ferrario A, Pulsoni A, Olivero B, et al. . Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation. Cancer. 2012;118(16):3954-3961.
- Bachy E, Seymour JF, Feugier P, et al. . Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol. 2019;37(31): 2815-2824.
- Vidal L, Gafter-Gvili A, Salles G, et al. . Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst. 2011;103(23):1799-1806.
- Cheson BD, Pfistner B, Juweid ME, et al. . Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586.
- Solal-Celigny P, Roy P, Colombat P, et al. . Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258-1265.
- Forstpointner R, Unterhalt M, Dreyling M, et al. . Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (RFCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108(13): 4003-4008.
- Martinelli G, Schmitz SF, Utiger U, et al. . Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol. 2010;28(29): 4480-4484.
- Barta SK, Li H, Hochster HS, et al. . Randomized phase 3 study in low-grade lymphoma comparing maintenance anti- CD20 antibody with observation after induction therapy: a trial of the ECOGACRIN Cancer Research Group (E1496). Cancer. 2016;122(19):2996-3004.
- Rummel M, Kaiser U, Balser C, et al. . Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, openlabel, non-inferiority phase 3 trial. Lancet Oncol. 2016;17(1):57-66.
- Rule S, Collins GP, Samanta K. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. J Med Econ. 2014;17(7):459-468.
- Rule S, Briones J, Smith R, et al. . Preference for rituximab subcutaneous (SC) and intravenous (IV) among patients with CD20+ non-Hodgkin's lymphoma (NHL) completing the RASQ measure In randomized phase III studies Prefmab and Mabcute. Value Health. 2014;17(7):A537.
- Sakai R, Ohmachi K, Sano F, et al. . Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study. Ann Hematol. 2019;98(9):2131-2138.
- Salar A, Avivi I, Bittner B, et al. . Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study. J Clin Oncol. 2014;32(17):1782-1791.
Source: PubMed